We are thrilled to announce that our latest research on the PIM2 kinase and its pivotal role in cellular stress response and tumor biology has been published in Nature Communications!

I've always been fascinated by how B cells differentiate into plasma cells—remarkable antibody factories that persist for decades in survival-promoting niches. This transformation is a high-stakes process, fraught with stress. How do plasma cells navigate this metamorphosis without succumbing to apoptosis?

Our study reveals that PIM2 kinase plays a crucial role in this differentiation, acting as a key regulator of plasma cell survival. This kinase operates on multiple levels, particularly at the mitochondria, by lowering the apoptosis threshold through inhibition of the integrated stress response (ISR) pathway.

In this article, we show that inhibiting PIM2 restores the ISR, leading to NOXA production and increased plasma cell dependence on MCL1. In tumor plasma cells, this mechanism reduces the apoptosis threshold, paving the way for synergistic effects with anti-myeloma therapies. An innovative xenograft model of myeloma cell lines in mice confirmed that combining PIM2 inhibition with MCL1 inhibition significantly enhances therapeutic efficacy.

Importantly, PIM2 is not only a key player in plasma cell biology but is also elevated in several solid cancers during their progression, highlighting its broader significance as a therapeutic target.

These findings offer exciting new insights into PIM2's role as a therapeutic target, unveiling novel strategies to exploit stress regulation pathways in cancer.

We invite you to explore our work and join the conversation on how these discoveries may shape future research and therapeutic approaches. Stay tuned for more updates and a link to the full article soon!

https://rdcu.be/d5oWe